Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

ABSTRACT:

Background

RET rearrangements are targetable, oncogenic lung cancer drivers. While previous series have shown durable clinical benefit with pemetrexed-based therapies in ALK- and ROS1-rearranged lung cancers, the benefits of pemetrexed-based treatments in patients with RET-rearranged lung cancers relative to other genomic subsets have not previously been explored.

Patients and methods

A retrospective review of patients with pathologically confirmed stage IIIB/IV lung adenocarcinomas and evidence of a RET, ROS1, or ALK rearrangement, or a KRAS mutation was conducted. Patients were eligible if they received treatment with pemetrexed alone or in combination. The primary outcome of progression-free survival (PFS), and secondary outcomes of overall response rate (ORR, RECIST v1.1

SUBMITTER: Drilon A 

PROVIDER: S-EPMC4922319 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature